Therapeutic Development Pipeline

Comprehensive overview of ZenthBio's investigational compounds, biologics, and platform technologies advancing through preclinical and clinical development stages.

24 Active Programs
12 In Clinical Trials
5 Commercialized
3 Platforms
ZB-8841
Target: EGFR / KRAS G12C
Active
IndicationNSCLC, Pancreatic Adenocarcinoma
AreaOncology
ModalitySmall Molecule
Lead SiteZenth Tower, Neo Geneva
DiscoveryPreclinPhase IPhase IIPhase III
Global Phase III registration trials initiated Q3 2025. Pooled analysis shows 42% improvement in progression-free survival vs standard of care.
ZB-5519
Target: SOD1 / TDP-43
Active
IndicationALS (Amyotrophic Lateral Sclerosis)
AreaNeurology
ModalityASO Therapy
Lead SiteLondon Biomedical Campus
DiscoveryPreclinPhase IPhase IIPhase III
Dose-escalation study completed. CSF biomarker reduction observed. Expanded access program launched for eligible patients.
ZB-3302
Target: PCSK9 / ANGPTL3
Active
IndicationFamilial Hypercholesterolemia
AreaCardiovascular
ModalityBispecific Antibody
Lead SiteMunich Clinical Research
DiscoveryPreclinPhase IPhase IIPhase III
First-in-human safety and PK/PD data positive. 6-month sustained LDL-C reduction anticipated with Q6W dosing.
ZB-9901
Target: SLC35A2
Active
IndicationSDC (Sialic Acid Storage Disease)
AreaRare Diseases
ModalityGene Therapy (AAV)
Lead SiteZenth Gene Therapeutics, Boston
DiscoveryPreclinPhase IPhase IIPhase III
IND-enabling studies underway. CNS delivery optimized via novel capsid engineering. Filing target: Q2 2027.
ZB-1120
Target: IL-17A / IL-17F
Commercial
IndicationPlaque Psoriasis, Psoriatic Arthritis
AreaImmunology
ModalityMonoclonal Antibody
BrandZenthera®
DiscoveryPreclinPhase IPhase IIPhase III
FDA/EMA approved 2024. Expanding indication label to axial spondyloarthritis. Peak sales projected $2.8B by 2028.
ZB-7742
Target: CDK4/6
On Hold
IndicationHR+/HER2- Breast Cancer
AreaOncology
ModalitySmall Molecule
Lead SiteTokyo Clinical Center
DiscoveryPreclinPhase IPhase IIPhase III
Development paused pending portfolio prioritization. Potential strategic partnership evaluation in progress.
ZB-0098
Target: Tau / Microtubule
Active
IndicationAlzheimer's Disease
AreaNeurology
ModalityFragment-based Lead
Lead SiteNeo Geneva Discovery Lab
DiscoveryPreclinPhase IPhase IIPhase III
High-throughput screening identified novel binding pocket. Structure-based optimization ongoing. Preclinical target: Q4 2026.
ZB-4410
Target: Sodium Channel
Terminated
IndicationHeart Failure
AreaCardiovascular
ModalitySmall Molecule
Lead SiteLondon Biomedical Campus
DiscoveryPreclinPhase IPhase IIPhase III
Program terminated Q2 2025 due to unfavorable safety signal in healthy volunteer cohort. Lessons integrated into next-gen series.